-
1
-
-
1842413105
-
The Non-Hodgkin's lymphoma classification project
-
A clinical evaluation of the international Lymphoma Study Group classification of non-Hodgkin's lymphoma
-
A clinical evaluation of the international Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
-
(1997)
Blood
, vol.89
, pp. 3909-3918
-
-
-
2
-
-
0031927984
-
New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
-
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histological subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795. (Pubitemid 28363044)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.8
, pp. 2780-2795
-
-
Armitage, J.O.1
Weisenburger, D.D.2
-
3
-
-
0027444652
-
The international non-Hodgkin's lymphoma prognostic factor project
-
A predictive model for aggressive non-Hodgkin's lymphoma
-
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 1993;329:987-994.
-
(1993)
N Engl J Med
, vol.329
, pp. 987-994
-
-
-
4
-
-
0027474009
-
Matrix metalloproteinases: A review
-
Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250. (Pubitemid 23103292)
-
(1993)
Critical Reviews in Oral Biology and Medicine
, vol.4
, Issue.2
, pp. 197-250
-
-
Birkedal-Hansen, H.1
Moore, W.G.I.2
Bodden, M.K.3
Windsor, L.J.4
Birkedal-Hansen, B.5
DeCarlo, A.6
Engler, J.A.7
-
5
-
-
0035116631
-
Tissue inhibitors of metalloproteases: Regulation and biological activities
-
DOI 10.1023/A:1006797522521
-
Fassina G, Ferrari N, Brigati C, et al. Tissue inhibitors of matrix metalloproteinanses: regulation and biological activities. Clin Exp Metastasis 2000;18:111-120. (Pubitemid 32165244)
-
(2000)
Clinical and Experimental Metastasis
, vol.18
, Issue.2
, pp. 111-120
-
-
Fassina, G.1
Ferrari, N.2
Brigati, C.3
Benelli, R.4
Santi, L.5
Noonan, D.6
Albini, A.7
-
6
-
-
15244348390
-
Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
-
DOI 10.1016/j.biochi.2005.01.014
-
Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and MMP-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005;87:287-297. (Pubitemid 40387607)
-
(2005)
Biochimie
, vol.87
, Issue.SPEC. ISS.
, pp. 287-297
-
-
Turpeenniemi-Hujanen, T.1
-
7
-
-
15244339896
-
The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma
-
DOI 10.1159/000086774
-
Kuvaja P, Talvensaari-Mattila A, Pääkkö P, et al. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1) but not for TIMP-2 protein is associated with a favourable prognosis in aggressive breast carcinoma. Oncology 2005;68:196-203. (Pubitemid 41158976)
-
(2005)
Oncology
, vol.68
, Issue.2-3
, pp. 196-203
-
-
Kuvaja, P.1
Talvensaari-Mattila, A.2
Paakko, P.3
Turpeenniemi-Hujanen, T.4
-
8
-
-
18244390735
-
Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and week squamous cell carcinoma: Comparison of the circulating and tissue immunoreactive protein
-
DOI 10.1158/1078-0432.CCR-04-2277
-
Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005;11:3257-3264. (Pubitemid 40627873)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.9
, pp. 3257-3264
-
-
Ruokolainen, H.1
Paakko, P.2
Turpeenniemi-Hujanen, T.3
-
9
-
-
30944455693
-
Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - Tissue immunoreactivity predicts aggressive clinical course
-
DOI 10.1038/modpathol.3800506, PII 3800506
-
Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 2006;19:208-217. (Pubitemid 43117605)
-
(2006)
Modern Pathology
, vol.19
, Issue.2
, pp. 208-217
-
-
Ruokolainen, H.1
Paakko, P.2
Turpeenniemi-Hujanen, T.3
-
10
-
-
0034688921
-
High levels of TIMP-2 correlate with adverse prognosis in breast cancer
-
Remacle A, McCarthy K, Noël A, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118-121. (Pubitemid 30185918)
-
(2000)
International Journal of Cancer
, vol.86
, Issue.3
, pp. 118-121
-
-
Remacle, A.1
McCarthy, K.2
Noel, A.3
Maguire, T.4
McDermott, E.5
O'Higgins, N.6
Foidart, J.M.7
Duffy, M.J.8
-
11
-
-
0041627545
-
Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas
-
DOI 10.1034/j.1600-0609.2003.00101.x
-
Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Gelatinases (MMP-2, MMP-9), TIMP-1 expression and extent of neovascularization in aggressive non-Hodgkin's lymphomas. Eur J Haematol 2003;71:91-99. (Pubitemid 36951641)
-
(2003)
European Journal of Haematology
, vol.71
, Issue.2
, pp. 91-99
-
-
Kuittinen, O.1
Apaja-Sarkkinen, M.2
Turpeenniemi-Hujanen, T.3
-
12
-
-
9144242962
-
Expression of Matrix Metalloproteinase 9 Is a Prognostic Factor in Patients with Non-Hodgkin Lymphoma
-
DOI 10.1002/cncr.11905
-
Sakata K, Satoh M, Someya M, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004;100:356-365. (Pubitemid 38063646)
-
(2004)
Cancer
, vol.100
, Issue.2
, pp. 356-365
-
-
Sakata, K.-I.1
Satoh, M.2
Someya, M.3
Asanuma, H.4
Nagakura, H.5
Oouchi, A.6
Nakata, K.7
Kogawa, K.8
Koito, K.9
Hareyama, M.10
Himi, T.11
-
13
-
-
33745207537
-
Clinicopathological implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma
-
Choi JW, An JS, Lee JH, et al. Clinicopathological implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. Mod Pathol 2006;19:963-973.
-
(2006)
Mod Pathol
, vol.19
, pp. 963-973
-
-
Choi, J.W.1
An, J.S.2
Lee, J.H.3
-
14
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
DOI 10.1038/35000501
-
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511. (Pubitemid 30082188)
-
(2000)
Nature
, vol.403
, Issue.6769
, pp. 503-511
-
-
Alizadeh, A.A.1
Elsen, M.B.2
Davis, R.E.3
Ma, Ch.L.4
Lossos, I.S.5
Rosenwald, A.6
Boldrick, J.C.7
Sabet, H.8
Tran, T.9
Yu, X.10
Powell, J.I.11
Yang, L.12
Maru, G.E.13
Moore, T.14
Hudson Jr., J.15
Lu, L.16
Lewis, D.B.17
Tibshirani, R.18
Sherlock, G.19
Chan, W.C.20
Greiner, T.C.21
Weisenburger, D.D.22
Armitage, J.O.23
Warnke, R.24
Levy, R.25
Wilson, W.26
Grever, M.R.27
Byrd, J.C.28
Botstein, D.29
Brown, P.O.30
Staudt, L.M.31
more..
-
15
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
DOI 10.1182/blood-2003-05-1545
-
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using tisue microarray. Blood 2004;103:275-282. (Pubitemid 38029949)
-
(2004)
Blood
, vol.103
, Issue.1
, pp. 275-282
-
-
Hans, C.P.1
Weisenburger, D.D.2
Greiner, T.C.3
Gascoyne, R.D.4
Delabie, J.5
Ott, G.6
Muller-Hermelink, H.K.7
Campo, E.8
Braziel, R.M.9
Jaffe, E.S.10
Pan, Z.11
Farinha, P.12
Smith, L.M.13
Falini, B.14
Banham, A.H.15
Rosenwald, A.16
Staudt, L.M.17
Connors, J.M.18
Armitage, J.O.19
Chan, W.C.20
more..
-
16
-
-
34249673388
-
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
-
DOI 10.1182/blood-2006-09-047068
-
Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-4935. (Pubitemid 46827791)
-
(2007)
Blood
, vol.109
, Issue.11
, pp. 4930-4935
-
-
Nyman, H.1
Adde, M.2
Karjalainen-Lindsberg, M.-L.3
Taskinen, M.4
Berglund, M.5
Amini, R.-M.6
Blomqvist, C.7
Enblad, G.8
Leppa, S.9
-
17
-
-
0742286867
-
Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma
-
DOI 10.1046/j.0902-4441.2004.00168.x
-
Pennanen H, Kuittinen O, Soini Y, et al. Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma. Eur J Haematol 2004;72:1-9. (Pubitemid 38161106)
-
(2004)
European Journal of Haematology
, vol.72
, Issue.1
, pp. 1-9
-
-
Pennanen, H.1
Kuittinen, O.2
Soini, Y.3
Turpeenniemi-Hujanen, T.4
-
18
-
-
33847361987
-
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
-
DOI 10.1182/blood-2006-08-038257
-
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
-
(2007)
Blood
, vol.109
, Issue.5
, pp. 1857-1861
-
-
Sehn, L.H.1
Berry, B.2
Chhanabhai, M.3
Fitzgerald, C.4
Gill, K.5
Hoskins, P.6
Klasa, R.7
Savage, K.J.8
Shenkier, T.9
Sutherland, J.10
Gascoyne, R.D.11
Connors, J.M.12
-
19
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
-
(2008)
N Engl J Med
, vol.359
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
-
20
-
-
54049126176
-
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study
-
Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-3098.
-
(2008)
Blood
, vol.112
, pp. 3088-3098
-
-
Young, K.H.1
Leroy, K.2
Møller, M.B.3
-
21
-
-
3042776316
-
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - A Nordic Lymphoma Group study
-
DOI 10.1007/s00277-004-0855-x
-
Jerkeman M, Anderson H, Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Ann Hematol 2004;83:414-419. (Pubitemid 38877961)
-
(2004)
Annals of Hematology
, vol.83
, Issue.7
, pp. 414-419
-
-
Jerkeman, M.1
Anderson, H.2
Dictor, M.3
Kvaloy, S.4
Akerman, M.5
Cavallin-Stahl, E.6
-
22
-
-
0028326055
-
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial
-
Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460-1466. (Pubitemid 24081556)
-
(1994)
Blood
, vol.83
, Issue.6
, pp. 1460-1466
-
-
Miller, T.P.1
Grogan, T.M.2
Dahlberg, S.3
Spier, C.M.4
Braziel, R.M.5
Banks, P.M.6
Foucar, K.7
Kjeldsberg, C.R.8
Levy, N.9
Nathwani, B.N.10
Schnitzer, B.11
Tubbs, R.R.12
Gaynor, E.R.13
Fisher, R.I.14
-
23
-
-
0030985194
-
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
-
Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251. (Pubitemid 27276568)
-
(1997)
Blood
, vol.90
, Issue.1
, pp. 244-251
-
-
Gascoyne, R.D.1
Adomat, S.A.2
Krajewski, S.3
Krajewska, M.4
Horsman, D.E.5
Tolcher, A.W.6
O'Reilly, S.E.7
Hoskins, P.8
Coldman, A.J.9
Reed, J.C.10
Connors, J.M.11
-
24
-
-
0037698992
-
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
-
DOI 10.1182/blood-2002-11-3442
-
Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. (Pubitemid 36857789)
-
(2003)
Blood
, vol.101
, Issue.11
, pp. 4279-4284
-
-
Mounier, N.1
Briere, J.2
Gisselbrecht, C.3
Emile, J.-F.4
Lederlin, P.5
Sebban, C.6
Berger, F.7
Bosly, A.8
Morel, P.9
Tilly, H.10
Bouabdallah, R.11
Reyes, F.12
Gaulard, P.13
Coiffier, B.14
-
25
-
-
33645791771
-
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study
-
DOI 10.1182/blood-2005-10-4222
-
Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213. (Pubitemid 43801342)
-
(2006)
Blood
, vol.107
, Issue.11
, pp. 4207-4213
-
-
Winter, J.N.1
Weller, E.A.2
Horning, S.J.3
Krajewska, M.4
Variakojis, D.5
Habermann, T.M.6
Fisher, R.I.7
Kurtin, P.J.8
Macon, W.R.9
Chhanabhai, M.10
Felgar, R.E.11
Hsi, E.D.12
Medeiros, L.J.13
Weick, J.K.14
Reed, J.C.15
Gascoyne, R.D.16
-
26
-
-
54049147790
-
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
-
Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433.
-
(2008)
Blood
, vol.112
, pp. 3425-3433
-
-
Rimsza, L.M.1
Leblanc, M.L.2
Unger, J.M.3
-
27
-
-
18744383031
-
Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma
-
DOI 10.1034/j.1600-0609.2002.02751.x
-
Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002;69:205-212. (Pubitemid 35448125)
-
(2002)
European Journal of Haematology
, vol.69
, Issue.4
, pp. 205-212
-
-
Kuittinen, O.1
Soini, Y.2
Turpeenniemi-Hujanen, T.3
-
28
-
-
0031431550
-
Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9
-
DOI 10.1016/S0959-8049(97)00186-X, PII S095980499700186X
-
Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 1997;33:1685-1692. (Pubitemid 28123494)
-
(1997)
European Journal of Cancer
, vol.33
, Issue.10
, pp. 1685-1692
-
-
Vacca, A.1
Moretti, S.2
Ribatti, D.3
Pellegrino, A.4
Pimpinelli, N.5
Bianchi, B.6
Bonifazi, E.7
Ria, R.8
Serio, G.9
Dammacco, F.10
-
29
-
-
0033134764
-
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
-
Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;9:3064-3073. (Pubitemid 29200799)
-
(1999)
Blood
, vol.93
, Issue.9
, pp. 3064-3073
-
-
Vacca, A.1
Ribatti, D.2
Presta, M.3
Minischetti, M.4
Iurlaro, M.5
Ria, R.6
Albini, A.7
Bussolino, F.8
Dammacco, F.9
-
30
-
-
0033769087
-
Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression
-
Vacca A, Ribatti D, Ria R, et al. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev Immunol 2000;7:77-88.
-
(2000)
Dev Immunol
, vol.7
, pp. 77-88
-
-
Vacca, A.1
Ribatti, D.2
Ria, R.3
-
31
-
-
0036790181
-
Increase in gelatinasespecificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model
-
Arlt M, Kopitz C, Pennington C, et al. Increase in gelatinasespecificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 2002;62:5543-5550.
-
(2002)
Cancer Res
, vol.62
, pp. 5543-5550
-
-
Arlt, M.1
Kopitz, C.2
Pennington, C.3
-
32
-
-
0031040059
-
Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92
-
Van Spronsen DJ, Vrints LW, Hofstra G, et al. Disappearence of prognostic significance of histopathological grading of nodular sclerosis Hodgkin's disease for unselected patients. Br J Haematol 1997;96:322-327. (Pubitemid 27077367)
-
(1997)
British Journal of Haematology
, vol.96
, Issue.2
, pp. 322-327
-
-
Van Spronsen, D.J.1
Vrints, L.W.2
Hofstra, G.3
Crommelin, M.A.4
Coebergh, J.W.W.5
Breed, W.P.M.6
-
33
-
-
0030825485
-
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma
-
Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1997;40(Suppl):S42-S46.
-
(1997)
Cancer Chemother Pharmacol
, vol.40
, Issue.SUPPL.
-
-
Fisher, R.I.1
-
34
-
-
3042813710
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
-
DOI 10.1182/blood-2003-06-2094
-
Pfreundschuh M, Trü mper L, Kloess M, et al. Twoweekly or 3 weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with goodprognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633. (Pubitemid 38970553)
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 626-633
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
Schmits, R.4
Feller, A.C.5
Rudolph, C.6
Reiser, M.7
Hossfeld, D.K.8
Metzner, B.9
Hasenclever, D.10
Schmitz, N.11
Glass, B.12
Rube, C.13
Loeffler, M.14
-
35
-
-
3242802160
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
-
DOI 10.1182/blood-2003-06-2095
-
Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of erderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641. (Pubitemid 38970554)
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 634-641
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
Schmits, R.4
Feller, A.C.5
Rube, C.6
Rudolph, C.7
Reiser, M.8
Hossfeld, D.K.9
Eimermacher, H.10
Hasenclever, D.11
Schmitz, N.12
Loeffler, M.13
-
36
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
DOI 10.1200/JCO.2005.09.137
-
Sehn LH, Donaldson J, Chhanabnai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033. (Pubitemid 46224009)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.22
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
Fitzgerald, C.4
Gill, K.5
Klasa, R.6
MacPherson, N.7
O'Reilly, S.8
Spinelli, J.J.9
Sutherland, J.10
Wilson, K.S.11
Gascoyne, R.D.12
Connors, J.M.13
-
37
-
-
48349126806
-
Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma
-
Nyman H, Jantunen E, Juvonen E, et al. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 2008;42:93-98.
-
(2008)
Bone Marrow Transplant
, vol.42
, pp. 93-98
-
-
Nyman, H.1
Jantunen, E.2
Juvonen, E.3
|